AIDS-related lymphoma patients with hypoalbuminemia show worse overall survival, two-year progression-free survival<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 24, 2022 (HealthDay News) — For patients with AIDS-related lymphoma (ARL), hypoalbuminemia predicts inferior outcome, according to a study published online June 18 in Infectious Agents and Cancer.<\/em><\/p>\n Jinxin Zhang, from Nanfang Hospital in Guangzhou, China, and colleagues retrospectively analyzed de novo ARL patients from 2013 to 2019 to examine factors correlating with progression-free survival (PFS) and overall survival (OS). Eighty-six ARL patients were enrolled and followed for a median of 34 months.<\/p>\n The researchers found that the OS and two-year PFS rates were 37.5 and 35.4 percent, respectively, in the cohort. Inferior survival was predicted by older age and hypoalbuminemia in multivariate models. Worse OS and two-year PFS were seen for ARL patients with hypoalbuminemia, which was associated with poor Eastern Cooperative Oncology Group performance status and a higher International Prognosis Index score.<\/p>\n “We showed that hypoalbuminemia is a simple and effective prognostic factor in AIDS-related lymphoma patients,” the authors write. “For ARL patients with hypoalbuminemia, closer follow-up and timely intervention are necessary.”<\/p>\n